“Tumor metabolism is a unique therapeutic approach that exploits the way in which cancer cells utilize nutrients to grow and survive,” said
Preclinical data suggest that CB-839, which is designed to starve tumor cells of the key nutrient glutamine, synergizes with CDK4/6 inhibitors by enhancing cell cycle arrest and blocking cancer cell proliferation. The combination of CB-839 with CDK4/6 inhibitors has demonstrated synergistic activity in a number of preclinical cancer models, including colorectal cancer (CRC), non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and ER+ breast cancer. Based on these data, Calithera will initiate a Phase 1/2 clinical trial of the combination of CB-839 plus palbociclib in patients with KRAS mutated CRC and patients with KRAS mutated NSCLC in the first quarter of 2019.
CB-839 also synergizes with PARP inhibitors to impair DNA synthesis, enhance DNA damage, and block cancer cell proliferation. The combination of CB-839 with PARP inhibitors has demonstrated synergistic activity in a number of preclinical cancer models, including renal cell carcinoma (RCC), TNBC, CRC, NSCLC, ovarian cancer and prostate cancer. Based on these data, Calithera will initiate a Phase 1/2 clinical trial of the combination of CB-839 plus talazoparib in patients with RCC, and TNBC in the first quarter of 2019.
About Calithera
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing and success of Calithera’s collaboration with Pfizer, the potential for CB-839 to be developed in combination with therapeutics, such as palbociclib or talazoparib, to improve patient outcomes, the safety, tolerability and efficacy of CB-839, the overall advancement of CB-839 in clinical trials, Calithera’s plans to continue development of CB-839 in combination with PARP inhibitor talazoparib for the treatment of TNBC, and RCC as well as the related timing for clinical trials, and Calithera’s plans to initiate a Phase 1/2 clinical trial of the combination of CB-839 plus palbociclib in CRC and NSCLC patients in the first quarter of 2019. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Annual Report on Form 10-K filed with the
SOURCE: Calithera Biosciences, Incorporated
CONTACT:
ir@Calithera.com
650-870-1071
Source: Calithera Biosciences, Inc.